NEOGENOMICS INC (NEO): Results of Operations and Financial Condition
NEOGENOMICS INC (NEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. October 05, 2026 Exhibit 99.1 NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan • Warren Stone, current President and COO, to become CEO and a member of the Board effective January 4, 2027 • Tony Zook to remain CEO through January 3, 2027 and becom
How this was made
The 30-second read
Why it matters
The announcement provides clarity on leadership continuity without altering financial targets.
Market read
The news is a primary disclosure of executive change and guidance reaffirmation, offering modest trading relevance.
What to watch
Potential integration of new CEO's prior experience at Merck could accelerate product pipelines.
NeoGenomics announced a CEO and Board succession plan and expects preliminary third quarter total revenue of approximately $209 million, including approximately 28% year-over-year NGS revenue growth.
The filing provides positive preliminary revenue and NGS growth indicators and says full-year revenue guidance is expected to increase, but it does not provide finalized financial statements, profitability, cash flow, balance-sheet figures, or the numerical full-year guidance range.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Third quarter total revenueother | approximately $209 million | – | – |
| Third quarter NGS revenue growthother | approximately 28% | – | approximately 28% |
full year 2026 outlook
- NoteTotal revenue and adjusted EBITDA guidance reiterated as provided on July 28, 2026.
- NoteFull year total revenue guidance expected to increase at midpoint resulting from third quarter performance.
What drove it
- Preliminary third quarter total revenue is expected to be approximately $209 million.
- NGS revenue growth is expected to be approximately 28% year-over-year.
- The Company expects an increase to full-year total revenue guidance resulting from third quarter performance.
- Management cited commercial expansion, customer impact, new product introductions, and Lab of the Future initiatives as key priorities.
Concerns
- The third quarter financial results are preliminary, unaudited and subject to completion.
- The consolidated financial statements for the third quarter of 2026 are not yet available and remain subject to quarter-end closing procedures and potential final adjustments.
- Actual results may differ materially from the preliminary results.
- The filing does not disclose gross margin, operating income, net income, EPS, cash flow, cash, debt, or a numerical full-year guidance range.
- The Company identified potential risks related to regulatory requirements for laboratory developed tests, tariffs and trade policy uncertainty, reimbursement changes, seasonality, customer growth, new test commercialization, and execution of strategic priorities.
What to watch
- Final third quarter 2026 financial results after closing procedures and potential final adjustments.
- The numerical increase to full-year total revenue guidance expected to be provided on the third quarter earnings call.
- Whether adjusted EBITDA guidance changes when additional third quarter details are provided.
- Execution of the CEO transition, with Warren Stone to become CEO effective January 4, 2027 and Tony Zook to become Executive Chairman effective January 4, 2027.
Analysis
This filing is a preliminary third quarter update rather than a complete earnings release. NeoGenomics expects to report third quarter total revenue of approximately $209 million for the quarter ended September 30, 2026. It also expects approximately 28% year-over-year NGS revenue growth. The filing provides no prior-year revenue amount, total revenue growth rate, or NGS revenue dollar amount.
The reported NGS growth is the principal operating-demand indicator in the release. Management also points to commercial expansion, customer impact, new product introductions, and Lab of the Future initiatives as strategic priorities. However, the filing does not provide segment revenue, test volumes, customer metrics, pricing, or any quantitative mix data, so the contribution of these initiatives cannot be measured from this document.
Profitability and cash generation cannot be assessed from the preliminary disclosure. The filing contains no gross margin, operating expenses, operating income, net income, EPS, operating cash flow, free cash flow, cash balance, debt balance, repurchases, or dividends. The Company states that its consolidated third quarter financial statements are not yet available, and that the preliminary results remain subject to closing procedures and potential final adjustments.
For the full year, NeoGenomics reiterated total revenue and adjusted EBITDA guidance as provided on July 28, 2026, while indicating that total revenue guidance is expected to increase at midpoint because of third quarter performance. Neither the existing guidance range nor the expected revised range is included in the filing. The next material financial catalyst is the third quarter earnings call, when the Company expects to provide further detail, including the revenue-guidance increase.
The filing also pairs the preliminary financial update with an executive and Board succession plan. Warren Stone is to become CEO and a Board member effective January 4, 2027, while Tony Zook is to become Executive Chairman effective the same date. The transition is presented as strategic continuity, but the filing provides no financial impact from the leadership changes.
Management, verbatim
This leadership transition reflects years of deliberate succession planning by the Board and cements the continuity of our executive team and a consistent strategy for durable, profitable growth at NeoGenomics.
Tony Zook, CEO
I believe that NeoGenomics is exceptionally well positioned to lead the evolution of the oncology diagnostics market in delivering the outcomes that matter most to patients and the physicians who care for them, and I am excited to partner with the remarkable NeoGenomics team to deliver our full potential.
Warren Stone, President and Chief Operating Officer
Not in the filing
stated, not guessed- Finalized third quarter 2026 financial statements
- Prior-year third quarter total revenue
- Third quarter total revenue year-over-year change
- Prior-quarter total revenue
- Third quarter gross profit and gross margin
- Third quarter operating expenses
- Third quarter operating income or loss
- Third quarter net income or loss
- Third quarter GAAP EPS
- Third quarter non-GAAP EPS
- Third quarter adjusted EBITDA
- Third quarter operating cash flow
- Third quarter free cash flow
- Cash balance
- Debt balance
- Capital returns, including share repurchases and dividends
- NGS revenue dollar amount
- Segment revenue and segment comparisons
- Test volumes, customer metrics, pricing, and revenue mix metrics
- Numerical full-year 2026 total revenue guidance range
- Numerical full-year 2026 adjusted EBITDA guidance range
- Numerical expected increase to full-year total revenue guidance
- Prior outlook figures needed to assess performance against prior guidance
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SEC Form 8‑K filing details executive succession and guidance reaffirmation.
Ticker impact
NeoGenomics announced a CEO succession plan and reaffirmed its full‑year revenue guidance.
likely modest pressure as the market prices in the executive change.
The succession is planned and does not alter financial outlook, so investors may view it as status‑quo.
Market effects
May signal stability in the oncology diagnostics sector.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
Leadership changes can uncover hidden strategic shifts that may boost growth.
Key entities
- companyNeoGenomics Inc.
Oncology diagnostics provider.
- personWarren Stone
Incoming CEO.
- personTony Zook
Outgoing CEO, becoming Executive Chair.
